key: cord-0841492-uzq7cetp authors: Sharma, Akanksha; Malviya, Rishabha; Kumar, Vinod; Gupta, Ramji; Awasthi, Rajendra title: Severity and risk of COVID‐19 in cancer patients: An evidence based learning date: 2020-06-08 journal: Dermatol Ther DOI: 10.1111/dth.13778 sha: d6070116db4acd05fe789c757b80a6b218345a9b doc_id: 841492 cord_uid: uzq7cetp The immune system of cancer patient gets compromised because of cancer therapy, surgery and malignancy and thus the probability of infection are increased than the general patients. Immunosuppression can expose cancer patients to serious complications which can lead to delay in diagnosis and unnecessary hospitalizations that may adversely affect the prognosis of the disease. Patients who received chemotherapy or surgery within the 30 days before COVID‐19 pandemic have more risk of infection than the patients who had not undergone chemotherapy or surgery. This article is protected by copyright. All rights reserved. Novel coronavirus disease (COVID-19) firstly observed in Wuhan, China in December 2019 [1] . Symptoms of COVID-19 infection usually developes in 2-14 days following virus exposure, which includes cough, fever, shortness of breath and pneumonia. Gastrointestinal, respiratory, hepatic and neurological complications caused by COVID-19 can lead to the death of patient. Till June 2, 2020, total 6140934 positive cases and 373548 deaths have been recorded worldwide due to COVID-19 infection (mortality rate: 6.32%) [2] . WHO region wise confirmed COVID-19 cases till June 2, 2020 are: Americas 2879316, Europe 2159791, Eastern Mediterranean 536148, South-East Asia 272512, Western Pacific 184305, Africa 108121 [3] . Cancer patients with hematological disorders or haematopoietic stem cell transplant are at high risk of COVID-19 infections due to the multiple comorbidities and immunosuppression. Several studies reported association of COVID-19 infection in cancer patients [4, 5] . Thus, there is emergent needed to create awareness in cancer patients to protect themselves from COVID-19. This communication compiles the data of severity and risk factors for cancer patients infected with COVID-19. Cancer patients have an immunosuppressed status, which can increase the risk of infection. Immunosuppression can expose cancer patients to serious complications due to an infection. This can delay the diagnosis and hospitalization of the patient and adversely affect medical prognosis. This article is protected by copyright. All rights reserved. A retrospective analysis of 355 Italian patients showed that 20% deaths with COVID-19 infection had active cancer. The study suggested that in the patients with leukemia, myeloma and lymphoma who receives radiotherapy, immunotherapy, chemotherapy, antibodies, poly ADP ribose polymerase inhibitors, protein kinase inhibitors and bone marrow or stem cell transplants can easily vulnerable to COVID-19 infection [5] . In a study population of 28 COVID-19 positive patients from Wuhan, China, lung cancer was most commonly diagnosed Wuhan. The severity of disease as sole criteria was accessed using SpO2 (obtained from pulse oximeter sensor) with a cut of 90%. The results showed that among 69 patients, four patients had a history of malignancy and only one patient had SpO2 < 90% [11] . Guan et al. analyzed the data of 1099 COVID-19 patients and reported that 261 patients (23.7%) with comorbidity in their cohort. Only ten patients (0.9%) had cancer history and three patients had severe symptoms on admission while the others had mild symptoms [12] . A comparative study consisting of 105 cancer patients and 536 patients with no history of cancer from Hubei Province, China has been reported that the cancer patients had higher death rate than non-cancer patients. The odds ratio of eight death was 2.17 after adjustment for covariates. The death rate was higher in patients with hematological cancer (33.33%, 9 deaths) and lung cancer (18.18%, 22 deaths), however the total number of deaths was low. This article is protected by copyright. All rights reserved. Metastatic cancer patients had high risk of death (odds ratio 5.58). A study reported 107 patients out of 44672 COVID-19 positive patients had cancer. COVID-19 infected patients with cancer had significantly higher risk of death than those without cancer (relative rate 2.93%, 6 deaths) [13] . Cancer patients intubated more frequently in a study population of 334 COVID-19 patients. However, the death rate did not differ significantly. It was observed that the cancer patient (66-80 years) had a high risk of intubation. Other age groups had non-significant difference in the risk of incubation. Cancer patients with less than 50 years of age had considerably higher mortality rate. However, COVID-19 mortality rates in cancer patients were lower than those in cancer-free patients in age groups over 50 years, although they were statistically nonsignificant [14] . Mehta infection. Mortality was 25% in all solid tumor patients and occurred at a high rate in gastrointestinal cancers (colorectal 38%), lung cancers (55%), pancreas (67%), gynecologic malignancies (38%) and upper gastrointestinal (38%). Genitourinary (15%) and breast cancer (14%) were also associated at relatively lower mortality with COVID-19 infection [15] . The cancer patients are immunocompromised due to the cancer therapy, surgery or malignancy. Such patients are at high risk to acquire COVID-19 infection. Particular measures should be taken by the cancer patients to avoid the risk of COVID-19 infection. Such patients should stay at home, avoid hospital visits and should opt tele or video consultation with healthcare providers. Authors have no conflict of interest. This article is protected by copyright. All rights reserved. Novel Coronavirus disease 2019 (COVID-19) and neurodegenerative disorders WHO Report on Coronavirus Disease (COVID-19) Pandemic. Available from WHO Coronavirus Disease (COVID-19) Dashboard. Available from Facing COVID-19 in the hematopoietic cell transplant setting: A new challenge for transplantation physicians Effect of the COVID-19 pandemic on cancer treatment and research. The Lancet Haematology How COVID-19 affects patients with cancer COVID-19 infection in cancer patients: How can oncologists deal with these patients? Front Oncol The impact of the COVID-19 pandemic on cancer patients Coronavirus disease 2019 (COVID-19): Cancer care during the pandemic A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China Clinical characteristics of coronavirus disease 2019 in China Patients with cancer appear more vulnerable to SARS-COV-2: A multicenter study during the COVID-19 outbreak Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City Case fatality rate of cancer patients with COVID-19 in a New York hospital system This article is protected by copyright. All rights reserved RA and RM conceived and designed the study. AS, VK and RG were responsible for literature search and screening. AS, VK, RM and RG were responsible for data collection.RM, RA, contributed to data interpretation. RM drafted the manuscript and RA analyses and critically revised the manuscript.